

AroCell signs distribution agreement in Ethiopia

AroCell continues to expand its sales and distribution network in Africa. Today, AroCell has signed a distribution agreement with Sub-Saharan Biomedical P.L.C. covering the sale of TUBEX® TF in Ethiopia.

Since launching in Africa, AroCell has focused on finding the right partners for distribution. The company has previously announced that agreements have been signed with distributors in Uganda, Ghana, and Kenya among others. AroCell has now signed a new distribution agreement with Sub-Saharan Biomedical P.L.C. for distribution in Ethiopia. The agreement covers the sale of the company's rapid test TUBEX® TF for typhoid fever.

"We look forward to collaborating with Sub-Saharan Biomedical PLC for the distribution and marketing of TUBEX® TF. Ethiopia is a large country with 120 million inhabitants and a potentially important market. We are continuously working on expanding into new markets and this is part of AroCell's strategy on the African continent", states Gunnar Wahlberg, Business Unit Director for Rapid tests at AroCell.

Contacts

Anders Hultman, CEO
Phone: +46 (0) 8 799 67 50
E-mail: anders.hultman@arocell.com

About AroCell

AroCell AB (publ) is a Swedish company that develops and markets blood and urine sample tests. The corporation specializes in oncology and bacteriology. The company has a broad product portfolio, used in healthcare, and established in various markets. In oncology, AroCell uses various biomarkers, TK1, and cytokeratins, to support the treatment of various cancers such as breast, prostate, and bladder cancers. AroCell's product portfolio also includes a rapid bacteriological test for a simple and safe diagnosis of typhoid fever. AroCell (AROC) is listed on Nasdaq First North Growth Market with Redeye AB as company's Certified Adviser. For more information; www.arocell.com

Attachments

[AroCell signs distribution agreement in Ethiopia](#)